Quanterix Corp (QTRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amid Regional ...

GuruFocus.com2024-10-10

Total Revenue: $34.4 million, an increase of 11% year-over-year. Accelerator Lab Revenue: $10.1 million, an increase of 35%. Consumable Revenue: $17.4 million, an increase of 7%. Instrument Revenue: $...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474078347?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BkRjiG8kOKTbtjfnqHD7sQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/ff88425cf7b5f01a66afddacaa64d8f7","is_english":true,"pubTime":"2024-10-10 05:55","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2474078347","market":"us","top_or_hot":-1,"title":"Quanterix Corp (QTRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amid Regional ...","media":"GuruFocus.com","content":"<div>\n<p>Total Revenue: $34.4 million, an increase of 11% year-over-year.\nAccelerator Lab Revenue: $10.1 million, an increase of 35%.\nConsumable Revenue: $17.4 million, an increase of 7%.\nInstrument Revenue: $...</p>\n\n<a href=\"https://finance.yahoo.com/news/quanterix-corp-qtrx-q2-2024-215540316.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quanterix Corp (QTRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amid Regional ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuanterix Corp (QTRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amid Regional ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-10 05:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/quanterix-corp-qtrx-q2-2024-215540316.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Total Revenue: $34.4 million, an increase of 11% year-over-year.\nAccelerator Lab Revenue: $10.1 million, an increase of 35%.\nConsumable Revenue: $17.4 million, an increase of 7%.\nInstrument Revenue: $...</p>\n\n<a href=\"https://finance.yahoo.com/news/quanterix-corp-qtrx-q2-2024-215540316.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/quanterix-corp-qtrx-q2-2024-215540316.html","article_id":"2474078347","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BkRjiG8kOKTbtjfnqHD7sQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/ff88425cf7b5f01a66afddacaa64d8f7"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474078347","pubTimestamp":1728510940,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Total Revenue: $34.4 million, an increase of 11% year-over-year.Instrument Revenue: $2.5 million, a decrease of 29%.GAAP Operating Expenses: $33.2 million, an increase of $4.5 million year-over-year.Non-GAAP Operating Expenses: $31.1 million, an increase of $4 million year-over-year.Cash and Liquidity: $299.5 million in cash, cash equivalents, marketable securities, and restricted cash.Cash Usage: Net outflow of $5.1 million for the quarter.Updated Full-Year 2024 Revenue Outlook: $134 million to $138 million, representing 11% growth at the midpoint.Revenue Growth by Region: North America up 15%, Europe up 25%, Asia Pacific down 36%.GuruFocus has detected 3 Warning Signs with QTRX.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Quanterix Corp  reported a total revenue of $34.4 million for Q2 2024, marking an 11% increase year-over-year.The Accelerator lab revenue grew by 35%, indicating strong demand for Simoa sensitivity without the n","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Quanterix Corp(QTRX)2024年第二季度收益看涨期权亮点：区域收入强劲增长……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QTRX":1},"content_text":"Total Revenue: $34.4 million, an increase of 11% year-over-year.\nAccelerator Lab Revenue: $10.1 million, an increase of 35%.\nConsumable Revenue: $17.4 million, an increase of 7%.\nInstrument Revenue: $2.5 million, a decrease of 29%.\nNon-GAAP Gross Margin: 52.3%.\nGAAP Gross Margin: 58.3%.\nGAAP Operating Expenses: $33.2 million, an increase of $4.5 million year-over-year.\nNon-GAAP Operating Expenses: $31.1 million, an increase of $4 million year-over-year.\nCash and Liquidity: $299.5 million in cash, cash equivalents, marketable securities, and restricted cash.\nCash Usage: Net outflow of $5.1 million for the quarter.\nUpdated Full-Year 2024 Revenue Outlook: $134 million to $138 million, representing 11% growth at the midpoint.\nRevenue Growth by Region: North America up 15%, Europe up 25%, Asia Pacific down 36%.\n\n\nWarning! GuruFocus has detected 3 Warning Signs with QTRX.\n\nRelease Date: August 08, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nQuanterix Corp (NASDAQ:QTRX) reported a total revenue of $34.4 million for Q2 2024, marking an 11% increase year-over-year.\nThe Accelerator lab revenue grew by 35%, indicating strong demand for Simoa sensitivity without the need for capital expenditure.\nThe company maintains a strong balance sheet with nearly $300 million in liquidity, supporting ongoing investments in growth.\nQuanterix Corp (NASDAQ:QTRX) has commercialized three new assays this quarter, with plans to complete 20 by the end of the year, enhancing their leadership in neurology.\nThe company has established new partnerships with major healthcare systems and labs, including Mount Sinai and UCSF, to expand Alzheimer's diagnostics.\n\n Negative Points \n\nInstrument revenue decreased by 29%, reflecting a challenging capital budget environment.\nThe Asia Pacific region, particularly China, saw a 36% decline in business, highlighting regional market challenges.\nNon-GAAP gross margin decreased by approximately 410 basis points compared to the previous year, due to investments in operations and quality framework.\nThe company anticipates higher cash usage at the upper end of their previous guidance due to lower revenue impacts.\nRevenue from patient testing under the loosened platform was immaterial for the quarter, indicating slower-than-expected uptake.\n\n Q & A Highlights \nQ: Given the capital equipment weakness over the past year, have you considered any potential reagent rental or financing options for instruments to drive pull-through? A: Yes, we have considered reagent rental programs, especially for customers with large consumable demand. Our accelerator program is a good offset for those without CapEx, allowing them to send samples to us.\nQ: With the FDA approval of Lilly's Kisumla, can you discuss your relationship with Lilly and any feedback on using blood-based biomarkers to drive therapeutic uptake? A: We are excited about the collaboration with Lilly on CertuitAD, which has resulted in a high accuracy test with a low indeterminate zone. This test evaluates patients as candidates for therapy, and we will continue to support and expand access.\nQ: What feedback have you received on the multi-marker approach to Alzheimer's disease testing, and do you expect it to be used predominantly over the standalone p-Tau 217 assay? A: The feedback has been positive, and we believe the future of blood-based testing will be multi-marker. Our multi-marker test reduces the intermediate zone while maintaining high accuracy, providing more certainty for symptomatic patients.\nQ: How quickly can large healthcare systems ramp up testing, and will they perform testing internally or send samples to you? A: Many partners have the capability to perform testing themselves, but they can also send samples to us if their capacity is exceeded. This flexibility is a unique aspect of the Quanterix Simoa offering.\nQ: With the FDA approval of Denenemab, have you noticed an uptick in interest in your diagnostic portfolio, and are we nearing an inflection point for Alzheimer's drugs? A: The drug ramp has been slower than anticipated, but with two FDA-approved therapies, we expect improvement. Blood-based testing will be key for first-line tests, and we are building infrastructure to support this growth.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474078347"}